Pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) (NSEIFSC:DRREDDY), on Tuesday introduced Versavo (bevacizumab) in the UK for treating various cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer.
Versavo, Dr. Reddy's first biosimilar product launched in the UK, is available in 100mg and 400mg single use vials.
Having debuted in India in 2019, Versavo was subsequently rolled out in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same name, while in Colombia, it was introduced under the brand name Persivia.
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer